Generation Bio (NASDAQ:GBIO) Given Outperform Rating at Wedbush

Generation Bio (NASDAQ:GBIO)‘s stock had its “outperform” rating reissued by Wedbush in a report released on Friday,RTT News reports. They presently have a $5.00 price objective on the stock.

Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 price target on shares of Generation Bio in a report on Friday.

Generation Bio Stock Down 2.7 %

Shares of NASDAQ:GBIO traded down $0.01 during midday trading on Friday, reaching $0.50. The company’s stock had a trading volume of 278,563 shares, compared to its average volume of 242,631. Generation Bio has a 1 year low of $0.47 and a 1 year high of $4.65. The business has a 50 day moving average price of $0.77 and a 200 day moving average price of $1.55. The firm has a market cap of $33.26 million, a price-to-earnings ratio of -0.23 and a beta of 2.72.

Generation Bio (NASDAQ:GBIO) last issued its earnings results on Wednesday, March 19th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.01). Generation Bio had a negative net margin of 782.86% and a negative return on equity of 104.85%. Sell-side analysts anticipate that Generation Bio will post -1.75 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Anthony G. Quinn acquired 125,791 shares of the company’s stock in a transaction on Friday, January 10th. The shares were purchased at an average price of $0.96 per share, for a total transaction of $120,759.36. Following the purchase, the director now owns 214,286 shares in the company, valued at $205,714.56. This represents a 142.14 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 21.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Generation Bio

Several institutional investors and hedge funds have recently added to or reduced their stakes in GBIO. Jefferies Financial Group Inc. bought a new stake in Generation Bio during the fourth quarter valued at about $2,398,000. Baker BROS. Advisors LP grew its stake in Generation Bio by 61.1% during the third quarter. Baker BROS. Advisors LP now owns 1,944,945 shares of the company’s stock worth $4,804,000 after buying an additional 737,988 shares during the last quarter. Renaissance Technologies LLC grew its stake in Generation Bio by 62.0% during the fourth quarter. Renaissance Technologies LLC now owns 962,959 shares of the company’s stock worth $1,021,000 after buying an additional 368,659 shares during the last quarter. Deutsche Bank AG increased its holdings in shares of Generation Bio by 688.7% during the fourth quarter. Deutsche Bank AG now owns 184,173 shares of the company’s stock worth $195,000 after buying an additional 160,822 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Generation Bio by 74.9% in the fourth quarter. JPMorgan Chase & Co. now owns 297,705 shares of the company’s stock valued at $316,000 after acquiring an additional 127,513 shares during the last quarter. 95.22% of the stock is currently owned by institutional investors and hedge funds.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.